Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons
about
Understanding natural herpes simplex virus immunity to inform next-generation vaccine designEvaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptionsFunctions of heat shock proteins in pathways of the innate and adaptive immune systemRecent advances in vaccine development for herpes simplex virus types I and IIGenital Herpes: Insights into Sexually Transmitted Infectious DiseaseCurrent status and prospects for development of an HSV vaccineProspects and perspectives for development of a vaccine against herpes simplex virus infections.Antibodies Are Required for Complete Vaccine-Induced Protection against Herpes Simplex Virus 2.Meta-Analysis on Randomized Controlled Trials of Vaccines with QS-21 or ISCOMATRIX Adjuvant: Safety and Tolerability.Peripheral blood CD4 T-cell and plasmacytoid dendritic cell (pDC) reactivity to herpes simplex virus 2 and pDC number do not correlate with the clinical or virologic severity of recurrent genital herpes.The challenge of developing a herpes simplex virus 2 vaccine.Herpes Simplex Vaccines: Prospects of Live-attenuated HSV Vaccines to Combat Genital and Ocular infections.T-cell immunity to human alphaherpesviruses.Generating protective immunity against genital herpesDistribution and effects of amino acid changes in drug-resistant α and β herpesviruses DNA polymeraseNasal Immunization Confers High Avidity Neutralizing Antibody Response and Immunity to Primary and Recurrent Genital Herpes in Guinea Pigs.HSV-2 vaccine: current status and insight into factors for developing an efficient vaccine.CD8+ T Lymphocyte Epitopes From The Herpes Simplex Virus Type 2 ICP27, VP22 and VP13/14 Proteins To Facilitate Vaccine Design And Characterization.Early events in herpes simplex virus lifecycle with implications for an infection of lifetimeHeat-shock proteins as dendritic cell-targeting vaccines--getting warmer.Antigenic breadth: a missing ingredient in HSV-2 subunit vaccines?Improving immunogenicity and efficacy of vaccines for genital herpes containing herpes simplex virus glycoprotein D.Vaccination to Reduce Reactivation of Herpes Simplex Virus Type 2.
P2860
Q26741484-C4C2551F-8224-4BC7-89DA-C614611346D4Q26777442-5D42AD5C-145C-4D90-9701-985AD9E32766Q26830705-9BD76A76-982B-46D7-8660-C3F1DC5E1C6EQ26859623-9D9F160A-EA43-4028-8D36-DE2EBD24455DQ30235026-32B51EB3-31D5-4C1D-822C-B8F51B41EE5FQ33931016-DEC8C3F2-FE17-4E7C-8A42-C406CA2A6CD4Q34431547-19045A8B-F7A0-40FC-AC23-5EDCB8ECE8A7Q35869527-99697AD7-B907-4079-9E5B-3CA5BA15570AQ36009558-624035B5-72DD-434D-BE2A-AB13EE81FD6BQ36246306-5A259035-B502-4D68-956D-0CFFA57F210BQ36671106-BF84BF88-EAFF-41B0-A2A0-6276A5E616DAQ36824210-003BB301-99D6-4B75-BB91-FC0D6C661FA1Q37107189-F0CF556B-C9A6-46D2-8DD9-1B8EF617917DQ37283993-B07E90ED-854F-4455-8D3D-6792512CCA8AQ37523020-7E4CB57A-44D8-4C7B-8FAF-E28A64017D58Q37531713-336644CA-8DD5-47F4-BCED-2C290E74183AQ37611796-19B47F4B-EA64-4B2B-807F-F74CA9F12AA9Q37679220-F91C4F1D-0F29-4E30-864C-D67D4DE09C24Q37980142-D10F316A-2939-4738-AA5A-456DDF995C94Q38095583-373460D0-4C34-4C00-8394-F7983ED46196Q38212516-53507FB1-FED4-462E-A1A9-C3D2DE9EE8C4Q38241377-4C86C013-FB2C-4693-ABBB-CB5F6682AA8DQ40223016-DA95A26A-E94B-40A9-80A7-C510C6FE1551
P2860
Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons
description
im September 2011 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 21 September 2011
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в листопаді 2011
@uk
name
Safety and immunogenicity of l ...... in HSV-2 seropositive persons
@en
Safety and immunogenicity of l ...... in HSV-2 seropositive persons
@nl
type
label
Safety and immunogenicity of l ...... in HSV-2 seropositive persons
@en
Safety and immunogenicity of l ...... in HSV-2 seropositive persons
@nl
prefLabel
Safety and immunogenicity of l ...... in HSV-2 seropositive persons
@en
Safety and immunogenicity of l ...... in HSV-2 seropositive persons
@nl
P2093
P1433
P1476
Safety and immunogenicity of l ...... in HSV-2 seropositive persons
@en
P2093
Cristina Musselli
Daniel L Levey
Kenneth Fife
Kenneth Leclair
Pramod K Srivastava
Roman M Chicz
Stephen Monks
Terri Warren
P304
P356
10.1016/J.VACCINE.2011.09.046
P407
P577
2011-09-21T00:00:00Z